Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Noradrenergic dysfunction and antidepressant treatment response.

H Corrêa1, F Duval, M M Claude

  • 1Centre Hospitalier, Section VIII, 68250, Rouffach, France. correa@task.com.br.

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|April 21, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Limb Girdle Muscular Dystrophy Associated With TRIM32 Variants: A National Cohort Study.

Muscle & nerve·2026
Same author

Search for Leptonic Decays of Dark Photons at NA62.

Physical review letters·2024
Same author

Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression.

L'Encephale·2023
Same author

Antiferromagnetic Blume-Capel model of the disordered Fe-Mn-Al ternary system.

Physical review. E·2022
Same author

Strategic placement of automated external defibrillators (AEDs) for cardiac arrests in public locations and private residences.

Resuscitation plus·2022
Same author

Temperature-dependent potential for the molecular dynamics of the superionic conductor β-PbF2.

Heliyon·2022

A blunted growth hormone (GH) response to clonidine (CLO) may predict antidepressant effectiveness in major depression. Patients with a blunted response showed better outcomes with amitriptyline (AMI) than fluoxetine (FLUOX).

Area of Science:

  • Neuroendocrinology
  • Psychopharmacology
  • Clinical Psychiatry

Background:

  • Major depressive disorder (MDD) diagnosis and treatment remain challenging.
  • Predictive biomarkers for antidepressant response are crucial for personalized medicine.
  • Hormonal responses to pharmacological challenges, like clonidine, are being explored as potential indicators.

Purpose of the Study:

  • To investigate if pretreatment hormonal response to clonidine differentiates antidepressant treatment outcomes in major depression.
  • To compare the efficacy of fluoxetine versus amitriptyline based on patients' baseline clonidine response.
  • To identify potential predictors of treatment success in major depressive patients.

Main Methods:

  • Sixty-two drug-free patients with recurrent major depression (DSM-IV criteria) and 20 healthy controls were assessed.

Related Experiment Videos

  • Patients received either fluoxetine (n=28) or amitriptyline (n=34) for 4 weeks.
  • Growth hormone (GH) response to clonidine (CLO) was measured (DeltaGH); patients were classified as responders or nonresponders based on the Hamilton Depression Rating Scale.

    • Main Results:

    • Depressed patients exhibited a significantly lower GH response to clonidine (DeltaGH) compared to controls (P<0.0002).
    • A blunted DeltaGH response was observed in 56% of depressed patients versus 5% of controls.
    • While overall antidepressant efficacy did not differ significantly between fluoxetine and amitriptyline, patients with a blunted DeltaGH showed a higher response rate to amitriptyline (11/21) compared to fluoxetine (1/14) (P<0.01).

    Conclusions:

    • A blunted growth hormone response to clonidine may serve as a predictive biomarker for antidepressant response in major depression.
    • This finding suggests that patients with a blunted neuroendocrine response might benefit more from certain antidepressant classes, like tricyclics (e.g., amitriptyline).
    • Further research is warranted to validate clonidine-induced hormonal changes as a clinical tool for guiding antidepressant selection.